Open AccessT790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
Author(s) -
Vinodini Merinda,
Gatot Soegiarto,
Laksmi Wulandari
Publication year - 2020
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_182_19
Subject(s) - t790m , medicine , epidermal growth factor receptor , cancer research , tyrosine kinase , adenocarcinoma , epidermal growth factor , oncology , receptor , gefitinib , cancer
Plasma circulating tumor deoxyribonucleic acid (ctDNA) test is an alternative method to detect the T790M mutation. Compared to conventional tumor rebiopsy, ctDNA possesses several advantages including less invasive, faster, lower costs, and having minimal risk of complications for patients.